Integrated Management of Pronation Deformity in Cerebral Palsy

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 17% of the time (276 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-03-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: trialivchildrennondiagnosis
  Phrases that lowered it: upperseverebotulinum toxinreceivedcommon
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 16.6% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Minimum age: 2 (lowers risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Design: parallel (raises risk) · Design
• Blinding: single (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 1.4% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 6074 (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 8 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A NCT03302871 · started 2016 · scored riskier than 12% of active trials completed
• Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial NCT02434549 · started 2015 · scored riskier than 50% of active trials terminated
• Phase III Clinical Trial of Botulax® to Treat Children With Cerebral Palsy NCT01787344 · started 2012 · scored riskier than 7% of active trials completed
• Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients NCT01821573 · started 2013 · scored riskier than 57% of active trials completed
• Comparative Hybrid Effects of Combining BoNT-A With Robot-assisted or Mirror Therapy for U/E Spasticity Stroke Patients NCT02749591 · started 2016 · scored riskier than 13% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.